# Ross Barrett

> Ross Barrett is a Series A investor at Cancer Focus Fund backing Biotechnology. See 8 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Firm: [Cancer Focus Fund](https://shizune.co/investors/profile/cancer-focus-fund)
- Location: Shreveport, United States
- Total investments: 8
- Last investment: Feb 2026
- Lead investor: 75%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/robarrett
- X (Twitter): http://twitter.com/secondcommand

Ross Barrett is a Series A investor at Cancer Focus Fund in Shreveport focused on Biotechnology and Medical. Ross Barrett is the Co-Founder, President, and Manager of Lagniappe Labs. He attended New York University School of Law.

## Contacts

5 contacts available for Ross Barrett: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/ross-barrett?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Medical | 2 | 25% |
| Health Care | 2 | 25% |
| Life Science | 2 | 25% |
| Therapeutics | 2 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Venture - Series Unknown | 3 | 38% |
| Seed | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 2 | 25% |
| United States | 2 | 25% |
| Germany | 1 | 13% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Starget Pharma | Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $18M | Series A | Feb 18, 2026 | http://www.stargetpharma.com |
| Starget Pharma | Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $5.1M | Venture - Series Unknown | Oct 23, 2024 | http://www.stargetpharma.com |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M | Series A | Oct 23, 2024 | https://march.bio/ |
| Eisbach Bio | Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria. | $4.5M | Venture - Series Unknown | Mar 21, 2024 | https://www.eisbach.bio |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $4.8M | Seed | Nov 09, 2023 | https://march.bio/ |
| ImmunoGenesis | ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. | $4.5M | Venture - Series Unknown | Jun 27, 2023 | https://www.immunogenesis.com/ |
| Nectin Therapeutics | Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $5.4M | Series A | Mar 07, 2022 | http://www.nectintx.com/ |

7 of 8 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 1 deal together
- BRF — VC Fund, 1 deal together
- [Fitz Gate Ventures](https://shizune.co/investors/profile/fitzrandolph-gateway) — VC Fund, 1 deal together
- [Ilex Medical](https://shizune.co/investors/profile/ilex-medical) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ross Barrett invest in?

Ross Barrett invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ross Barrett?

Public channels for Ross Barrett include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Ross Barrett last invest?

The most recent investment recorded for Ross Barrett closed in Feb 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co